78.63
-2.03 (-2.51%)
| Previous Close | 80.65 |
| Open | 80.86 |
| Volume | 126,417 |
| Avg. Volume (3M) | 571,647 |
| Market Cap | 2,968,106,240 |
| Price / Book | 3.73 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 4.64% |
| Current Ratio (MRQ) | 37.65 |
| Operating Cash Flow (TTM) | -101.70 M |
| Levered Free Cash Flow (TTM) | -66.74 M |
| Return on Assets (TTM) | -16.25% |
| Return on Equity (TTM) | -23.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Disc Medicine, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -1.10 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.65% |
| % Held by Institutions | 99.13% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 125.00 (Cantor Fitzgerald, 58.98%) | Buy |
| Median | 100.00 (27.19%) | |
| Low | 78.00 (Wells Fargo, -0.80%) | Buy |
| Average | 100.20 (27.44%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 65.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 17 Feb 2026 | 100.00 (27.19%) | Buy | 65.57 |
| Cantor Fitzgerald | 17 Feb 2026 | 125.00 (58.98%) | Buy | 65.57 |
| Stifel | 17 Feb 2026 | 110.00 (39.90%) | Buy | 65.57 |
| Wedbush | 17 Feb 2026 | 88.00 (11.92%) | Buy | 65.57 |
| Wells Fargo | 17 Feb 2026 | 78.00 (-0.79%) | Buy | 65.57 |
| 16 Dec 2025 | 109.00 (38.63%) | Buy | 91.47 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FRANCHI JEAN M. | - | 65.03 | -11,156 | -723,781 |
| KHARA RAHUL | - | 65.57 | -2,853 | -187,071 |
| QUISEL JOHN D | - | 65.57 | -13,264 | -869,720 |
| SAVAGE WILLIAM JACOB | - | 65.57 | -3,256 | -213,496 |
| STEPHENSON PAMELA | - | 65.57 | -5,531 | -362,668 |
| YU JONATHAN YEN-WEN | - | 65.57 | -3,231 | -211,857 |
| Aggregate Net Quantity | -39,291 | |||
| Aggregate Net Value ($) | -2,568,593 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 65.41 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FRANCHI JEAN M. | Officer | 18 Feb 2026 | Automatic sell (-) | 7,081 | 64.48 | 456,583 |
| QUISEL JOHN D | Officer | 17 Feb 2026 | Sell (-) | 13,264 | 65.57 | 869,720 |
| YU JONATHAN YEN-WEN | Officer | 17 Feb 2026 | Sell (-) | 3,231 | 65.57 | 211,857 |
| SAVAGE WILLIAM JACOB | Officer | 17 Feb 2026 | Sell (-) | 3,256 | 65.57 | 213,496 |
| STEPHENSON PAMELA | Officer | 17 Feb 2026 | Sell (-) | 5,531 | 65.57 | 362,668 |
| KHARA RAHUL | Officer | 17 Feb 2026 | Sell (-) | 2,853 | 65.57 | 187,071 |
| FRANCHI JEAN M. | Officer | 17 Feb 2026 | Sell (-) | 4,075 | 65.57 | 267,198 |
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 |
| 12 Jan 2026 | Announcement | Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer |
| 07 Jan 2026 | Announcement | Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 06 Dec 2025 | Announcement | Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |